CH
Therapeutic Areas
KalVista Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| EKTERLY® (sebetralstat) | Hereditary Angioedema (HAE) - On-demand treatment | Approved/Commercial |
| Sebetralstat | HAE - On-demand treatment in pediatric patients (2-11 years) | Phase 3 |
| Oral Factor XIIa Inhibitors | HAE - Prophylactic treatment | Preclinical |
Leadership Team at KalVista Pharmaceuticals
BL
Benjamin L. Palleiko
Chief Executive Officer and Director
BA
Bilal Arif
Chief Operating Officer
LA
Linea Aspesi
Chief People Officer
PK
Paul K. Audhya, MD, MBA
Chief Medical Officer
BK
Brian Krex, JD
General Counsel
RM
Rachel M. Morten
Senior Vice President, Regulatory Affairs and QA
BP
Brian Piekos
Chief Financial Officer
MD
Michael D. Smith, PharmD
Senior Vice President of Development
NS
Nicole Sweeny
Chief Commercial Officer
CM
Christopher M. Yea, PhD
Chief Development Officer